Impact Biomedical (IBO) Enterprise Value (2024 - 2026)

Impact Biomedical (IBO) has reported Enterprise Value for 3 consecutive years, with $52.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 415.07% year-over-year to $52.8 million; the trailing twelve-month figure through Jun 2026 stood at $52.8 million (up 415.07% YoY), and the FY2025 full-year result was $19.0 million, up 7.68% from the prior year.
• Enterprise Value retreated to $52.8 million in Q2 2026 per IBO's latest filing, from $67.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $67.9 million in Q1 2026 and bottomed at $10.3 million in Q2 2025.
• Historically, Enterprise Value has averaged $26.8 million across 3 years, with a median of $18.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value tumbled 52.41% in 2025, then jumped 458.4% in 2026.
• Over 3 years, Enterprise Value stood at $17.7 million in 2024, then rose by 7.68% to $19.0 million in 2025, then soared by 177.84% to $52.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $52.8 million, $67.9 million, and $19.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.